Anil Jain: Last News

Bajaj Healthcare launches favipiravir drug Favijaj for covid treatment

₹583.05 on the BSE, up 10.85% from previous close. Favipiravir is an antiviral drug, which has shown potent in vitro activity against severe acute respiratory syndrome of coronavirus, the company said in a release.“We are pleased to add Favipiravir to our growing product portfolios.

The second wave is more aggressive and bigger in number than the first. We hope the availability of an effective treatment such as Favijaj will considerably ease the pressure, and offer patients much needed and timely therapy option," said Anil Jain, Joint Managing Director at Bajaj Healthcare.The company said it has developed the active pharmaceutical ingredient (API) and the formulation for favipiravir through its own in-house R&D team.“The drug controller of

. Waves

Anil Jain

www.livemint.comwww.livemint.com